2013
Ink4a/Arf−/− and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f− quiescent cells
Kai K, Iwamoto T, Kobayashi T, Arima Y, Takamoto Y, Ohnishi N, Bartholomeusz C, Horii R, Akiyama F, Hortobagyi GN, Pusztai L, Saya H, Ueno NT. Ink4a/Arf−/− and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f− quiescent cells. Oncogene 2013, 33: 440-448. PMID: 23376849, PMCID: PMC3957346, DOI: 10.1038/onc.2012.609.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p16FemaleFlow CytometryImmunohistochemistryIntegrin alpha6Mammary Neoplasms, ExperimentalMiceMice, Inbred C57BLMice, KnockoutNeoplastic Stem CellsOligonucleotide Array Sequence AnalysisProto-Oncogene Proteins p21(ras)Real-Time Polymerase Chain ReactionTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerHuman triple-negative breast cancerBreast cancerTumor-initiating potentialIntratumoral heterogeneityInk4a/Claudin-low breast cancerMouse mammary tumor modelNon-mammary tumorsHigh tumor-initiating potentialMouse mammary fat padMammary cellsMammary fat padMammary tumor modelIndividual breast tumorsTumor precursor cellsQuiescent cellsTumor-initiating cellsPathological featuresProgesterone receptorMammary tumorsEstrogen receptorAnimal modelsFat padBreast tumors
2012
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer
Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 5832-5837. PMID: 22460789, PMCID: PMC3326451, DOI: 10.1073/pnas.1201105109.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCalcium-Binding ProteinsCD24 AntigenCell DifferentiationCell DivisionEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, NeoplasmHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinMembrane ProteinsMiceNeoadjuvant TherapyNeoplastic Stem CellsPrognosisReceptor, ErbB-2Serrate-Jagged ProteinsSignal TransductionTrastuzumabTreatment OutcomeConceptsTumor-initiating cellsMammary tumor-initiating cellsBreast cancerClinical outcomesPrognostic signatureHuman epidermal growth factor receptorAnti-HER2 drugsAnti-HER2 therapyHigh-risk patientsHigh-risk subgroupsEpidermal growth factor receptorGrowth factor receptorBC cohortRisk patientsAggressive diseaseBC patientsRetrospective analysisImmune responsePrognostic powerTumor growthPatientsChemotherapyFactor receptorCancerFraction of cells